Carbon ion radiation therapy for chordomas and low grade chondrosarcomas - current status of the clinical trials at GSI-

2004 ◽  
Vol 73 ◽  
pp. S53-S56 ◽  
Author(s):  
Daniela Schulz-Ertner ◽  
Anna Nikoghosyan ◽  
Bernd Didinger ◽  
Jürgen Debus
Keyword(s):  
Clinical Trials ◽  
Radiation Therapy ◽  
Current Status ◽  
Low Grade ◽  
Carbon Ion

scholarly journals Clinical trials involving carbon‐ion radiation therapy and the path forward

Cancer ◽  
2018 ◽  
Vol 124 (23) ◽  
pp. 4467-4476 ◽  
Author(s):  
Ann A. Lazar ◽  
Reinhard Schulte ◽  
Bruce Faddegon ◽  
Eleanor A. Blakely ◽  
Mack Roach
Keyword(s):  
Clinical Trials ◽  
Radiation Therapy ◽  
Carbon Ion

scholarly journals Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 163 ◽  
Author(s):  
Mikaela Dell’Oro ◽  
Michala Short ◽  
Puthenparampil Wilson ◽  
Eva Bezak
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Survival Rate ◽  
Particle Therapy ◽  
Current Status ◽  
Published Data ◽  
Carbon Ion Therapy ◽  
Carbon Ion ◽  
Ion Therapy

Introduction: Despite improvements in radiation therapy, chemotherapy and surgical procedures over the last 30 years, pancreatic cancer 5-year survival rate remains at 9%. Reduced stroma permeability and heterogeneous blood supply to the tumour prevent chemoradiation from making a meaningful impact on overall survival. Hypoxia-activated prodrugs are the latest strategy to reintroduce oxygenation to radioresistant cells harbouring in pancreatic cancer. This paper reviews the current status of photon and particle radiation therapy for pancreatic cancer in combination with systemic therapies and hypoxia activators. Methods: The current effectiveness of management of pancreatic cancer was systematically evaluated from MEDLINE® database search in April 2019. Results: Limited published data suggest pancreatic cancer patients undergoing carbon ion therapy and proton therapy achieve a comparable median survival time (25.1 months and 25.6 months, respectively) and 1-year overall survival rate (84% and 77.8%). Inconsistencies in methodology, recording parameters and protocols have prevented the safety and technical aspects of particle therapy to be fully defined yet. Conclusion: There is an increasing requirement to tackle unmet clinical demands of pancreatic cancer, particularly the lack of synergistic therapies in the advancing space of radiation oncology.

Carbon ion radiation therapy for chordomas and low grade chondrosarcomas of the skull base

2001 ◽  
Vol 51 (3) ◽  
pp. 163
Author(s):  
D. Schulz-Ertner ◽  
J. Debus ◽  
T. Haberer ◽  
O. Jaekel ◽  
C. Thilmann ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Skull Base ◽  
Low Grade ◽  
Carbon Ion

scholarly journals External dosimetry audit for quality assurance of carbon-ion radiation therapy clinical trials

2018 ◽  
Vol 20 (1) ◽  
pp. 31-36 ◽  
Author(s):  
Hideyuki Mizuno ◽  
Akifumi Fukumura ◽  
Nobuyuki Kanematsu ◽  
Shunsuke Yonai ◽  
Toshiyuki Shirai ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Quality Assurance ◽  
Radiation Therapy ◽  
Carbon Ion

Physical and Biological Basis of Proton and of Carbon Ion Radiation Therapy and Clinical Outcome Data

2009 ◽  
Vol 02 (01) ◽  
pp. 1-15 ◽  
Author(s):  
Herman Suit ◽  
Thomas F. Delaney ◽  
Alexei Trofimov
Keyword(s):  
Clinical Trials ◽  
Radiation Therapy ◽  
Dose Distribution ◽  
Particle Beam ◽  
Initial Energy ◽  
Outcome Data ◽  
Ion Beams ◽  
Phase Iii ◽  
Dose Fractionation ◽  
Carbon Ion

There is a clear basis in physics for the clinical use of proton and carbon beams in radiation therapy, namely, the finite range of the particle beam. The range is dependent on the beam initial energy, density and atomic composition of tissues along the beam path. Beams can be designed that penetrate to the required depth and deliver a uniform biologically effective dose across the depth of interest. The yield is a superior dose distribution relative to photon beams. There is a potential clinical advantage from the high linear energy transfer (LET) characteristics of carbon beams. This is based on a lower oxygen enhancement ratio (OER) and a flatter age response function. However, due to uncertainties relating OER with relative biological effectiveness (RBE), there is no clinical evidence to date that carbon ion beams have an advantage over proton beams. We strongly support performance Phase III clinical trials of protons vs carbon ion beams designed to feature a single variable, LET. Dose fractionation would be identical in both arms and dose distribution would be similar for the sites to be tested. For sites for which the carbon beam has a demonstrated important advantage in comparative treatment planning due to the narrower penumbra would not be selected for the clinical trials.

Combined stereotactic split-course fractionated gamma knife radiosurgery and conventional radiation therapy for unfavorable gliomas: a phase I study

2000 ◽  
Vol 93 (supplement_3) ◽  
pp. 37-41 ◽  
Author(s):  
William F. Regine ◽  
Roy A. Patchell ◽  
James M. Strottmann ◽  
Ali Meigooni ◽  
Michael Sanders ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Disease Progression ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
External Beam Radiation ◽  
Low Grade ◽  
Beam Radiation ◽  
Content Type ◽  
Group B ◽  
Fine Print

Object. This investigation was performed to determine the tolerance and toxicities of split-course fractionated gamma knife radiosurgery (FSRS) given in combination with conventional external-beam radiation therapy (CEBRT). Methods. Eighteen patients with previously unirradiated, gliomas treated between March 1995 and January 2000 form the substrate of this report. These included 11 patients with malignant gliomas, six with low-grade gliomas, and one with a recurrent glioma. They were stratified into three groups according to tumor volume (TV). Fifteen were treated using the initial FSRS dose schedule and form the subject of this report. Group A (four patients), had TV of 5 cm3 or less (7 Gy twice pre- and twice post-CEBRT); Group B (six patients), TV greater than 5 cm3 but less than or equal to 15 cm3 (7 Gy twice pre-CEBRT and once post-CEBRT); and Group C (five patients), TV greater than 15 cm3 but less than or equal to 30 cm3 (7 Gy once pre- and once post-CEBRT). All patients received CEBRT to 59.4 Gy in 1.8-Gy fractions. Dose escalation was planned, provided the level of toxicity was acceptable. All patients were able to complete CEBRT without interruption or experiencing disease progression. Unacceptable toxicity was observed in two Grade 4/Group B patients and two Grade 4/Group C patients. Eight patients required reoperation. In three (38%) there was necrosis without evidence of tumor. Neuroimaging studies were available for evaluation in 14 patients. Two had a partial (≥ 50%) reduction in volume and nine had a minor (> 20%) reduction in size. The median follow-up period was 15 months (range 9–60 months). Six patients remained alive for 3 to 60 months. Conclusions. The imaging responses and the ability of these patients with intracranial gliomas to complete therapy without interruption or experiencing disease progression is encouraging. Excessive toxicity derived from combined FSRS and CEBRT treatment, as evaluated thus far in this study, was seen in patients with Group B and C lesions at the 7-Gy dose level. Evaluation of this novel treatment strategy with dose modification is ongoing.

Sign in / Sign up

Export Citation Format

Share Document